Nano-X Imaging Q1 Loss Widens; Shares Down By 21%
Nano-X Imaging Ltd. (NNOX) reported a wider Q1 2026 loss of $14.27M ($0.20/share) vs. $13.24M ($0.21/share) in Q1 2025. Adjusted net loss was $11.13M ($0.16/share) vs. $9.24M ($0.15/share). Revenue rose to $4.31M from $2.82M. Shares fell 20.82% to $0.7370.
How this was made
The 30-second read
Why it matters
The widened loss and modest revenue increase led to a 21% share decline, indicating short‑term bearish sentiment.
Market read
Earnings miss for a micro‑cap biotech could trigger further downside and influence sector peers.
What to watch
Potential upcoming regulatory approvals or partnership announcements not covered in this release.
Background
Nano-X Imaging Ltd. (NNOX) provides tomographic imaging devices and reported its Q1 2026 financial results.
Ticker impact
Q1 2026 loss widened to $14.27M and shares fell 21% on the Nasdaq.
downward pressure, potential further decline if guidance remains weak
The company reported larger losses than a year ago and revenue growth was modest, triggering a 21% price drop.
Market effects
Highlights challenges in the medical imaging equipment sector, may affect peer valuations.
Limited to U.S. biotech/medical device investors.
Low global impact due to company's small market cap.
Counterpoint
If the company can accelerate revenue growth, the price dip may present a buying opportunity.
Key entities
- CompanyNano-X Imaging Ltd.
Medical imaging device manufacturer listed on Nasdaq under NNOX.
